{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:40:19Z","timestamp":1787506819554,"version":"build-2736575974"},"reference-count":24,"publisher":"Japan Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0494","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T17:16:04Z","timestamp":1738343764000},"page":"365-373","source":"Crossref","is-referenced-by-count":3,"title":["Characteristics of patients with Graves\u2019 disease who developed drug resistance and required surgery"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4804-7428","authenticated-orcid":false,"given":"Yusuke","family":"Shibata","sequence":"first","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Shinshu University School of Medicine, Nagano 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7765-9466","authenticated-orcid":false,"given":"Ako","family":"Oiwa","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Shinshu University School of Medicine, Nagano 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Okaya City Hospital, Nagano 394-0028, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-9789","authenticated-orcid":false,"given":"Satoshi","family":"Kubota","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Shinshu University School of Medicine, Nagano 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine, Nagano 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhisa","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Shinshu University School of Medicine, Nagano 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 T\u00f6rring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, et al. (1996) Graves\u2019 hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine\u2014a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 81: 2986\u20132993.","DOI":"10.1210\/jcem.81.8.8768863"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Mori T, Sugawa H, Kosugi S, Ueda M, Hai N, et al. (1997) Recent trends in the management of Graves\u2019 hyperthyroidism in Japan: opinion survey results, especially on the combination therapy of antithyroid drug and thyroid hormone. Endocr J 44: 509\u2013517.","DOI":"10.1507\/endocrj.44.509"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3 Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, et al. (1991) Differences and similarities in the diagnosis and treatment of Graves\u2019 disease in Europe, Japan, and the United States. Thyroid 1: 129\u2013135.","DOI":"10.1089\/thy.1991.1.129"},{"key":"#cr-split#-4.1","unstructured":"4 Japan Thyroid Association (2019) What are the indications for drug therapy? In: Japan Thyroid Association"},{"key":"#cr-split#-4.2","unstructured":"(ed) Graves' Disease Treatment Guidelines 2019. Nankodo, Tokyo, Japan: 36-37 (In Japanese)."},{"key":"5","unstructured":"5  (2022) Thyroid Disease Diagnostic Guidelines 2021. Japan Thyroid Association. Tokyo, Japan. https:\/\/www.japanthyroid.jp\/doctor\/guideline\/japanese.html#basedou accessed on September 30, 2024 (In Japanese)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, et al. (1990) Antithyroid drugs and Graves\u2019 disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 70: 675\u2013679.","DOI":"10.1210\/jcem-70-3-675"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Garc\u00eda-Mayor RV, P\u00e1ramo C, Luna Cano R, P\u00e9rez Mendez LF, Galofr\u00e9 JC, et al. (1992) Antithyroid drug and Graves\u2019 hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest 15: 815\u2013820.","DOI":"10.1007\/BF03348811"},{"key":"8","unstructured":"8 Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM (1994) Treatment of Graves\u2019 disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med 87: 337\u2013341."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, et al. (1999) Antithyroid drugs and Graves\u2019 disease\u2014prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 50: 127\u2013132.","DOI":"10.1046\/j.1365-2265.1999.00629.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS (2010) Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst Rev 2010: Cd003420.","DOI":"10.1002\/14651858.CD003420.pub4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Takamatsu J, Sugawara M, Kuma K, Kobayashi A, Matsuzuka F, et al. (1984) Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves\u2019 disease. Ann Intern Med 100: 372\u2013375.","DOI":"10.7326\/0003-4819-100-3-372"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Matsumoto C, Ito M, Yamada H, Yamakawa N, Yoshida H, et al. (2013) Genes that characterize T3-predominant Graves\u2019 thyroid tissues. Eur J Endocrinol 168: 137\u2013144.","DOI":"10.1530\/EJE-12-0507"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Takamatsu J, Kuma K, Mozai T (1986) Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves\u2019 disease. J Clin Endocrinol Metab 62: 980\u2013983.","DOI":"10.1210\/jcem-62-5-980"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Ito M, Toyoda N, Nomura E, Takamura Y, Amino N, et al. (2011) Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3'-triiodothyronine-predominant Graves\u2019 disease. Eur J Endocrinol 164: 95\u2013100.","DOI":"10.1530\/EJE-10-0736"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Benker G, Vitti P, Kahaly G, Raue F, Tegler L, et al. (1995) Response to methimazole in Graves\u2019 disease. The European Multicenter Study Group. Clin Endocrinol (Oxf) 43: 257\u2013263.","DOI":"10.1111\/j.1365-2265.1995.tb02030.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Takahashi S, Ito M, Masaki Y, Hada M, Minakata M, et al. (2021) Association between serum thyroid hormone balance and thyroid volume in patients treated with levothyroxine monotherapy for hypothyroidism. Endocr J 68: 353\u2013360.","DOI":"10.1507\/endocrj.EJ20-0542"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ito M, Miyauchi A, Morita S, Kudo T, Nishihara E, et al. (2012) TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur J Endocrinol 167: 373\u2013378.","DOI":"10.1530\/EJE-11-1029"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Ito M, Miyauchi A, Kang S, Hisakado M, Yoshioka W, et al. (2015) Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients. Eur J Endocrinol 173: 333\u2013340.","DOI":"10.1530\/EJE-15-0138"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Ito M, Kawasaki M, Danno H, Kohsaka K, Nakamura T, et al. (2019) Serum thyroid hormone balance in levothyroxine monotherapy-treated patients with atrophic thyroid after radioiodine treatment for Graves\u2019 disease. Thyroid 29: 1364\u20131370.","DOI":"10.1089\/thy.2019.0135"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR (2005) Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 115: 2524\u20132533.","DOI":"10.1172\/JCI25083"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR (2002) Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23: 38\u201389.","DOI":"10.1210\/edrv.23.1.0455"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Harada A, Nomura E, Nishimura K, Ito M, Yoshida H, et al. (2019) Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with huge goitrous Hashimoto\u2019s thyroiditis. Endocrine 64: 584\u2013590.","DOI":"10.1007\/s12020-019-01855-7"},{"key":"23","unstructured":"23 Fukata S, Ito M (2013) Characteristics and treatment precautions of T3-dominant Graves disease. J Medl J 4672: 58\u201359 (In Japanese)."}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/4\/72_EJ24-0494\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:19:44Z","timestamp":1743812384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/4\/72_EJ24-0494\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0494","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0494"}}